Vander Heiden MG, Cantley LC, Thompson CB
Biopharma companies face: Massive competition and potential market saturation with over 500 GLP-1-related clinical trials across 100+ indications Downward price pressure Highly restricted reimbursement and resistance to new indications Mechanism-based stratification can: Enrich clinical trials for responders (response biomarkers) Identify strong responder subgroups (complementary diagnostic) Differentiate competing assets Support development in new indications (biomarker-led indication switching) De-risk late-stage programs (clinical trial design) Past efforts to expand GLP-1s into new indications - such as the semaglutide Alzheimers trial - largely targeted broad patient groups defined by their clinical symptoms or diagnostic labels
[24] In another human clinical trial conducted on a sample of pulmonary tuberculosis patients, epitalon did not appear to correct pre-existing structural aberrations of chromosomes associated with telomere degradation, but did appear to exert a protective effect against the future development of additional chromosomal aberrations
Average number of x-rays per patient also reduced from 4.1 to 2.9 (p = 0.16), with an increase in bridle utilisation (32% to 75% p = 0.032)
While this might partly subcellular compartmentation and the lower reducing power (higher redox potential) of ascorbate compared to glutathione, NADH, and NADPH, it also points to efficient co-operation between the various isoforms of the three reductases
.png)
